Wednesday, August 25, 2010
Ovarian cancer often presents at an advanced stage, but tends to be an intra-peritoneal disease that respects peritoneal planes. Thus, colo-rectal perforation of the tumor is an extremely rare presentation. The surgical treatment of malignant colo-ovarian fistula should include complete cyto-reduction at the same time as the treatment of the fistula. However, prognosis remains poor, because of the advanced stage of neoplasia. We report the case of a patient with an ovarian malignant tumor perforating into the recto-sigmoid colon. CT scan was the cornerstone of the radiological diagnosis. We managed to perform a complete cyto-reduction, including an en-bloc resection of the uterus, the mass, adnexa and recto-sigmoid with removal of the associated pelvic abscess.
Ovarian teratoma is a type of germ cell tumour. Germ cell tumours are cancers that begin in egg cells in women or sperm cells in men. There are two main types of ovarian teratoma
* Mature teratoma, which is benign
* Immature teratoma, which is cancerous
Background: The most common type of ovarian germ cell tumor is the teratoma. Thyroid tissue, both benign and malignant, may be a component of an ovarian teratoma. Here we review this topic and illustrate major features by presenting multimodal management of a patient with BRAF-positive disseminated follicular thyroid cancer arising in an ovarian teratoma.
Conclusions: Aggressive multimodal management appears to be the most promising approach for malignant thyroid tissue arising in ovarian teratomas.
in research - Abstract: RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
CONCLUSIONS: Our data provides kinase targets that could be exploited to design better therapeutics for ovarian cancer patients. We also demonstrate the effectiveness of high-throughput RNAi screening as a tool for identifying sensitizing targets to known and established chemotherapeutic agents.
|Australian: ovarian cancer clinical practice guidelines (teal star)|
Note: again with this update, the Australian ovarian cancer guidelines are in plain english and comprehensive; chapter 4 discusses briefly familial risks noting that HNPCC (hereditary non polyposis colorectal cancer) is now more commonly known as Lynch Syndrome; it would have been preferable to include the actual Lynch Syndrome commonly screened mutations (MSH2/MSH6/MLH1 & PMS2)
Promoting clinical best practice in the treatment of ovarian cancer:
NBOCC is currently reviewing and updating selected topics in its Clinical practice guidelines for the management of women with epithelial ovarian cancer, to provide Australian health professionals with timely, evidence-based information.....A evidence review has been completed to inform the development of updated recommendations about the follow-up care of women with ovarian cancer, including patient preferences
article/opinion piece: Canadian medical Association - CMA Emerges Dazed from Cave, Writes Report :: Longwoods.com
About the Author
Steven Lewis, President Access Consulting Ltd., Saskatoon & Adjunct Professor of Health Policy, University of Calgary and Simon Fraser University
The need for oncogenetic counselling. Ten years' experience of a regional oncogenetic clinic - abstract
Checking it twice: an evaluation of checklists for detecting medication errors at the bedside using a chemotherapy model - patient safety
Main outcome measures
Rates of specified types of errors related to medication administration.
As few as 0% and as many as 90% of each type of error were detected.
Body Mass Index Increases Risk of Colorectal Adenomas in Men With Lynch Syndrome: The GEO Lynch Cohort Study
CONCLUSION Excess body weight increased the risk of incident colorectal adenomas in people with LS (Lynch Syndrome). This increased risk was seen only in men.